Related Experiment Video
Updated: May 9, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Polymorphism of ITGB2 gene 3'-UTR+145C/A is associated with biliary atresia
Insights
Genetic variations in the ITGB2 gene may influence biliary atresia (BA) risk. A specific polymorphism in the ITGB2 3'-UTR region was significantly associated with increased BA susceptibility in infants.
Area of Science:
- Genetics
- Pediatric Hepatology
- Molecular Biology
Background:
- Biliary atresia (BA) is a severe infant liver disease with unknown etiology.
- Potential causes include infectious, immune, and genetic factors.
- Investigating genetic susceptibility is crucial for understanding BA.
Purpose of the Study:
- To determine if ITGB2 (CD18) gene polymorphisms are associated with biliary atresia (BA) susceptibility.
- To identify specific genetic variants that may contribute to BA pathogenesis.
Main Methods:
- Genotyping of the ITGB2 gene promoter and 16 exons in 106 BA patients and 108 controls.
- Association analysis using Fischer's exact test.
- Reporter gene assay to evaluate the functional impact of identified polymorphisms.
Main Results:
- Six single nucleotide polymorphisms (SNPs) in the ITGB2 gene were identified: one in the promoter and five in exons.
- No significant differences in genotype or allelic frequencies were found for most SNPs.
- The 3'-UTR+145C/A polymorphism showed a significantly higher C allele frequency and CC genotype in BA patients (p=0.0006).
- Reporter gene assays confirmed higher activity for the risk allele (3'-UTR+145 C).
Conclusions:
- The ITGB2 3'-UTR+145C/A polymorphism is associated with an increased risk of biliary atresia.
- This finding suggests a potential role for ITGB2 in BA pathogenesis.
- Further research is warranted to elucidate the precise mechanisms involved.
Background And Study Aims:
Biliary atresia (BA) is a devastating disease of infants, invariably leading to cirrhosis, end-stage liver disease, and death if untreated. The etiology of BA is unknown, although infectious, immune, and genetic causes have been suggested. This study was designed to investigate whether polymorphism of the ITGB2 (CD18) gene is associated with susceptibility to BA.
Methods:
The ITGB2 gene promoter and 16 exons were genotyped following amplification and sequencing, with associations assessed using Fischer's exact test in 106 patients diagnosed with BA and 108 unrelated healthy controls.
Results:
We found one single nucleotide polymorphism (SNP) in the ITGB2 promoter region (-680 C/T) and five SNPs in exons, including: -111 T/C in exon 1, 117 G/A in exon 3, 819 G/A in exon 7, 1101 C/A in exon 10, and 3'-UTR+145C/A in exon 16. There were no significant differences in genotype and allelic frequencies of any of the SNPs between controls and patients with BA in both the promoter and exons 1, 3, 7, and 10. 3'-UTR+145C/A showed a significant increase in the C allele frequency (OR = 2.19, 95% CI: 1.39-3.46, p = 0.0006) and a significant increase in the CC genotype (p = 0.001) in BA patients compared with healthy controls. Using a reporter gene assay, the construct that contained the risk allele (3'-UTR+145 C) showed significantly higher luciferase activity than the nonrisk A allele (p = 0.007).
Conclusion:
Our study provides the first evidence of a possible role of ITGB2 3'-UTR+145C/A polymorphism in the pathogenesis of BA.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Multiple Allele Traits
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Genetic Lingo
Pleiotropy
Pedigree Analysis

